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Abstract Chemoresistance is one of the major hurdles to
overcome for the successful treatment of breast cancer. At
present, there are several mechanisms proposed to explain
drug resistance to chemotherapeutic agents, including
decreased intracellular drug concentrations, mediated by
drug transporters and metabolic enzymes; impaired cellular
responses that affect cell cycle arrest, apoptosis, and DNA
repair; the induction of signaling pathways that promote
the progression of cancer cell populations; perturbations
in DNA methylation and histone modifications; and
alterations in the availability of drug targets. Both genetic
a n de p i g e n e t i ct h e o r i e sh a v eb e e np u tf o r w a r dt oe x p l a i n
the mechanisms of drug resistance. Recently, a small
non-coding class of RNAs, known as microRNAs, has
been identified as master regulators of key genes
implicated in mechanisms of chemoresistance. This
a r t i c l er e v i e w st h er o l eo f microRNAs in regulating
chemoresistance and highlights potential therapeutic
targets for reversing miRNA-mediated drug resistance.
In the future, microRNA-based treatments, in combination
with traditional chemotherapy, may be a new strategy for the
clinical management of drug-resistant breast cancers.
Keywords microRNA.Drug resistance.Breast cancer
Introduction
Breast cancer is the most common malignancy in women
that affected an estimated three million women worldwide in
2008 alone (Jemal et al. 2011). Current treatment strategies
combine surgery with adjuvant therapy, such as cytotoxic
anticancer drugs, hormonal therapy, targeted drugs, or a
combination thereof. It is estimated that one of two breast
cancer patients will fail to respond to initial treatments or
will rapidly acquire resistance to chemotherapeutic agents
(O’Driscoll and Clynes 2006). Moreover, the majority of
cancer patients, even if they show an initial response to
treatment, will develop aggressive malignancies, which
exhibit up to 90% resistance to one or more drugs (Ellis
and Hicklin 2009; Sorrentino et al. 2008). This clearly
suggests that drug resistance, whether intrinsic or acquired
over time, constitutes a major hurdle to overcome for the
successful treatment of breast cancer.
The underlying mechanisms of the acquisition of
resistance to chemotherapeutic agents are still poorly
understood. Presently, two main hypotheses, genetic and
epigenetic, have been proposed to explain the basis of
cancer drug resistance (Baker and El-Osta 2003; Glasspool
et al. 2006; Iwasa et al. 2006; Lee et al. 2011). The term
“genetic” is commonly used to define a heritable change
in the DNA sequence, and according to this model,
drug-induced mutational events select for drug-resistant
cell populations (Iwasa et al. 2006). Conversely, the
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gene expression that occur without altering the sequence
of DNA, through processes such as DNA methylation
and histone modifications (Egger et al. 2004), and
suggests that changes in the epigenome facilitates
resistance to cytotoxic drugs (Baker and El-Osta 2003;
G l a s s p o o le ta l .2006).
Although evidence regarding genetic changes following
chemotherapeutic treatment is limited, numerous studies
have demonstrated substantial epigenetic alterations in
drug-resistant cancer cells (Baker et al. 2005; Roberti et
al. 2006). It is well documented that epigenetic dysregula-
tion of genes, whose products modulate the intracellular
concentration of anticancer agents, such as the multidrug-
resistant 1 (MDR1) gene, breast cancer resistance protein
(BCRP) gene, and glutathione S-transferase π (GSTπ) gene,
influences drug efficacy (Baker et al. 2005; Chekhun et al.
2006). Additionally, alterations in DNA repair proteins,
including O
6-methylguanine DNA methyltransferase, and
increased expression of proteins involved in cell signaling
pathways that promote cancer cell survival have been
associated with cytosine methylation and histone modifica-
tions, clearly indicating the importance of epigenetic
mechanisms in drug resistance (Chekhun et al. 2006,
2007; Starlard-Davenport et al. 2010). Furthermore, acqui-
sition of resistance has been associated with profound
dysregulation of the epigenomic landscape, suggesting that
epigenetic changes may be a driving force in acquiring
resistance to anticancer agents (Baylin 2011; Glasspool et
al. 2006).
In addition to these well-studied mechanisms of cancer
drug resistance, recent studies have linked the acquisition of
cancer drug resistance to altered expression of microRNAs
(miRNAs; Kovalchuk et al. 2008; Liang et al. 2010;
Pogribny et al. 2010; Zhao et al. 2008). Evidence of
miRNA-mediated drug resistance is accumulating, and
much attention is now being focused on targeting miRNAs
as a novel strategy for therapeutic intervention. Future
studies will be necessary to address the clinical significance
and feasibility of implementing miRNA-based approaches
to modulate sensitivity to chemotherapeutic agents.
This review focuses on the role of miRNAs in acquiring
the drug-resistant phenotype and how dysregulation of the
miRNAome may contribute to the cross-resistance of
cancer cells to various chemotherapeutic agents.
miRNA biogenesis and function in normal and tumor
cells
miRNAs are 16- to 29-nucleotide-long single-stranded
RNA sequences that function at the post-transcriptional
level to negatively regulate gene expression (Bartel 2004;
Guo et al. 2010a; Zhang et al. 2009). These mature
miRNAs arise from a multistep process (Fig. 1) in which
they are first transcribed as long primary transcripts (pri-
miRNA) by RNA polymerase II (Lee et al. 2004) or RNA
polymerase III (Borchert and LanierW 2006). Nuclear
cleavage of the pri-miRNA by Drosha, a RNase III-type
enzyme, liberates an ∼60- to 70-nucleotide stem loop
intermediate known as the miRNA precursor (pre-miRNA;
Filippov et al. 2000; Snyder et al. 2009). These precursor
miRNAs are then transported from the nucleus to the
cytoplasm by Exportin-5 for further processing by a second
RNase III enzyme, Dicer (Kim et al. 2009). The double-
stranded complex is unwound to free the mature strand for
incorporation into a RNA-induced silencing complex,
leaving the second strand to be degraded. Through
sequence-specific interactions between the mature miRNA
and mRNA, the ribonucleoprotein complex is positioned on
either the 3′-o r5 ′-untranslated region (UTR) of their
targets, resulting in mRNA cleavage if complementarity is
perfect or, in the case of imperfect base pairing, transla-
tional repression (Bartel 2004; Kim et al. 2009; Guo et al.
2010a; Selbach et al. 2008).
Currently, more than 1,200 mammalian miRNAs have
been identified that can potentially target up to one third
of the protein-coding genes (The miRBase Sequence
Database—Release 16.0) involved in development, cell
differentiation, metabolic pathways, signal transduction,
proliferation, and apoptosis (Bartel 2004; Selbach et al.
2008). Given that cancer is characterized by the deregu-
lation of these very same biological processes (Hanahan
and Weinberg 2011), hypothetical conjectures, confirmed
by empirical evidence, have indicated that aberrant
miRNA expression may play an important role in cancer
(Ruan et al. 2009). Indeed, the list of miRNAs found to be
up- or down-regulated in cancer, whose targets are tumor
suppressor genes or oncogenes, respectively, is rapidly
expanding (Andorfer et al. 2011; Garofalo and Croce 2011),
and these dysregulated miRNAs have been associated with
every aspect of tumor biology, including tumor progression,
invasion, metastasis, and acquisition of resistance to various
chemotherapeutic agents (Aigner 2011;B l o w e re ta l .2007;
Kastl et al. 2011;K o r p a le ta l .2008;M ae ta l .2010;
Pogribny et al. 2010).
miRNAs and mechanisms of drug resistance in breast
cancer
At present, there are several mechanisms proposed to
explain drug resistance to chemotherapeutic agents,
including (1) decreased intracellular drug concentrations,
mediated by drug transporters and metabolic enzymes;
(2) impaired cellular responses that affect cell cycle
172 Clin Epigenet (2011) 2:171–185arrest, apoptosis, and DNA repair; (3) the induction of
signaling pathways that promote the malignant transfor-
mation and invasiveness of cell populations; (4) pertur-
bations in DNA methylation and histone modifications;
and (5) alterations in the availability of drug targets.
These mechanisms have recently been shown to be
targeted by miRNAs in drug-resistant breast cancer
(Table 1; Kovalchuk et al. 2008;L i a n ge ta l .2010;
Pogribny et al. 2010;X i ne ta l .2009).
miRNAs in defensive mechanisms
Defensive mechanisms, such as the up-regulation of drug
transporters and metabolic enzymes, play an important role
in regulating absorption, distribution, and clearance of
chemotherapeutic agents and their metabolites (Baguley
2010; Gatti and Zunino 2005). Recent miRNA profiling
studies have identified a subset of target genes involved in
drug efflux and metabolism (Kovalchuk et al. 2008; Pan et
al. 2009; Pogribny et al. 2010; Xin et al. 2009).
Chemotherapeutic failure is often attributed to increases
in energy-dependent drug efflux, mediated via A TP-binding
cassette (ABC) drug transporters (Gottesman and Ling 2006).
The classic representative of this family is P-glycoprotein
(P-gp) encoded by the MDR1 gene (Gottesman and Ling
2006) whose overexpression has been associated with
cellular resistance to a wide variety of anticancer agents,
including anthracycline antibiotics, plant alkaloids, taxanes,
and platinum-based drugs (Allen et al. 2003;Z u n i n oe ta l .
1999). One hypothesis to explain P-gp-mediated resistance
is a marked decrease of miR-451, which was directly
correlated to elevated levels of its target, P-gp, in MCF-7
cells resistant to doxorubicin (Kovalchuk et al. 2008).
Furthermore, MCF-7 cells transfected with miR-451
exhibited enhanced sensitivity to doxorubicin (Kovalchuk
et al. 2008). Similarly, BCRP , which shares drug substrates
with P-gp (Allen et al. 2003), is also a target for miRNA
regulation, specifically miR-328 (Pan et al. 2009;X i ne t
al. 2009).
Another subfamily of the ABC transporter family, the
multidrug resistance-associated proteins (MRPs), acts on a
number of drugs, including glutathione (GSH)-conjugated
derivatives (Jedlitschky et al. 1996; Konig et al. 1999).
Indeed, resistance to cisplatin has been correlated with
MRP2-mediated efflux of cisplatin–GSH complexes (Konig
et al. 1999; Siddik 2002, 2003). Currently, miR-489 is
being explored as a putative regulator of MRP2 whose
down-regulation is associated with resistance to cisplatin
and doxorubicin (Kovalchuk et al. 2008; Pogribny et al.
2010). Studies in our lab have further demonstrated the
importance of miRNA-mediated regulation of MRP in
which miR-7 and miR-345 were found to target directly
the 3′-UTR of the MRP1 transcript (Pogribny et al. 2010).
Decreased levels of these miRNAs conferred resistance to
7MGpppG                            AAAAA
Imperfect Complementarity
Perfect
Complementarity
Cytoplasm Nucleus
RNA
Pol II
miRNA gene
Pasha
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Pri-miRNA
Dicer
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Fig. 1 miRNA biogenesis and function. Mature miRNAs arise from a
multistep process in which they are first transcribed by RNA
polymerase II (RNA pol II) as a primary miRNA (pri-miRNA)
transcript. After being cleaved in the nucleus by the RNAse III
ribonuclease, Drosha, and its cofactor Pasha, the precursor miRNA
(pre-miRNA) is exported to the cytoplasm by Exportin 5, where it is
cleaved by a second RNAse III ribonuclease, Dicer. This 16- to 29-
nucleotide-long miRNA duplex is then unwound to free the mature
strand for incorporation into a RNA-induced silencing complex
(RISC) and, based on sequence complementarity, directs translational
repression or cleavage of its mRNA target by binding to either the 3′-
or 5′-untranslated (UTR) regions
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176 Clin Epigenet (2011) 2:171–185cisplatin in MCF-7 cells (Pogribny et al. 2010). Additionally,
loss of miR-326 in MCF-7/VP multidrug-resistant cell lines
contributed to the overexpression of MRP1, whereas
enforced levels of this miRNA sensitized MCF-7/VP to
VP-16 and doxorubicin (Liang et al. 2010). Similar
associations were observed in a panel of advanced breast
cancers in which decreased levels of miR-326 consistently
exhibited an inverse correlation with MRP1 expression
levels (Liang et al. 2010).
Sensitivity to chemotherapeutic agents is also modulated
by the rate of metabolic clearance. Increased drug
metabolism, mediated by the induction of phase I and
phase II enzymes, has been correlated with decreased
responses to breast cancer treatment (Ingelman-Sundberg
and Rodriguez-Antona 2005). Our findings link the up-
regulation of cytochrome P450 enzymes, CYP1B1 and
CYP3A4, with the down-regulation of miR-27 and a
subsequent increase in doxorubicin metabolism (Kovalchuk
et al. 2008).
Reversal of drug resistance is of great importance for
establishing effective chemotherapeutic practices. In light
of recent research indicating a prominent role of miRNAs
in reversing resistance to a wide range of drugs (Zhang et
al. 2010; Zhao et al. 2010a), miRNA-mediated regulation
of drug transporters and metabolic enzymes may prove to
be a promising strategy to regulate the absorption,
distribution, and clearance of chemotherapeutic agents.
miRNAs in cellular responses to chemotherapeutic agents
Cytotoxic drugs, such as doxorubicin, paclitaxel, and
cisplatin, primarily function by damaging the genetic
material of cells, thereby interfering with the ability of
cancer cells to divide. Several distinct cellular responses are
activated to cope with genotoxic damage, including the
induction of cell cycle arrest and, if the damage exceeds the
cellular capacity for repair, the induction of apoptosis. The
fine tuning of pro- and anti-apoptotic programs, which are
carefully balanced by miRNAs in normal cells, is shifted
toward cell survival in cancerous cells.
Cell cycle arrest
DNA damage is detected by sensor molecules, such as p53,
which then initiate checkpoint responses that block the
activity of cyclin-dependent kinases (CDKs) and conse-
quently halt cell cycle progression. Loss of p53 is
associated with decreased sensitivity to DNA damage and
drug resistance. One mechanism to explain this decreased
sensitivity is the up-regulation of miR-125, which binds to
the 3′-UTR of the p53 gene to block translation (Le et al.
2009) in cell lines resistant to paclitaxel and doxorubicin
(Kovalchuk et al. 2008; Zhao et al. 2008). The downstream
effects of this response are numerous because p53 activates
the expression of several important cell regulatory genes,
including cyclin-dependent kinase inhibitor p21
(CDKN1A). Moreover, miR-20, which targets p21
(CDKN1A; Trompeter et al. 2011) is up-regulated in
drug-resistant cell lines (Kovalchuk et al. 2008), further
decreasing the levels of this negative cell cycle regulator.
Loss of p21, which normally binds to CDK2 to prevent
cells from entering the S-phase, may be one of the
mechanisms enabling cancer cells to progress through the
cell cycle with DNA damage. The G1/S checkpoint is also
targeted by several other miRNAs dysregulated in drug-
resistant breast cancers, including miR-221/222 and miR-
214 (Kovalchuk et al. 2008; Pogribny et al. 2010; Zhao et
al. 2008), both of which target PTEN (Garofalo et al. 2009;
Li et al. 2011), a CDK inhibitor, and the miR-16 family,
miR-29, miR-34, and miR-107 (Liang et al. 2010;
Kovalchuk et al. 2008; Pogribny et al. 2010), which target
CDK6 (Feng et al. 2011; Liu et al. 2008; Sun et al. 2008;
Zhao et al. 2010b).
CDKs, when bound to their cyclin counterparts,
actively phosphorylate substrates to regulate the entry
of the cell into the cell cycle. Phosphorylation of RB
releases E2F, which enters the nucleus to activate the
transcription of cell cycle-related genes to promote the
cell’s entry into the S-phase. Both RB and E2F are
targets for miRNA repression, including miR-17, miR-20,
miR-34, miR-93, miR-106, miR-205, and miR-331 (Dar
et al. 2011; Guo et al. 2010b; Tazawa et al. 2007;
Trompeter et al. 2011) whose expression is dysregulated
in genotoxic drug resistance (Kovalchuk et al. 2008;
Pogribny et al. 2010). The inhibitory phosphate group
can be removed by cell division control proteins (CDC),
which are also a target for miRNAs, including miR-29 and
miR-224 (Park et al. 2009;Z h ue ta l .2010a), both of
which are up-regulated in drug-resistant cells (Kovalchuk
et al. 2008; Liang et al. 2010;P o g r i b n ye ta l .2010).
To add further to the complexity, there are many
miRNAs dysregulated in chemoresistant cell lines
(Kovalchuk et al. 2008;L i a n ge ta l .2010; Xin et al.
2009) that target cyclins directly, including let-7, miR-16,
miR-17, and miR-34 (Liu et al. 2008; Schultz et al. 2008;
Sun et al. 2008;Y ue ta l .2008). Clearly, miRNAs play a key
role in regulating cell cycle progression in drug-resistant cell
lines by targeting mRNA at several different stages.
Apoptosis
The ability to evade programmed cell death is one of the
hallmarks of cancer cells (Hanahan and Weinberg 2011).
Cytotoxic drugs, such as cisplatin, are designed to
reactivate apoptotic pathways by inducing stress pathways,
such as via p38, or by suppressing MAPK/AKT signaling
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AKT through the up-regulation of several oncogenic
miRNAs that target PTEN (e.g., miR-22, miR-205,
miR-214, and miR221/222; Bar and Dikstein 2010;
Garofalo et al. 2009;G r e e n ee ta l .2010;L ie ta l .2011),
a negative regulator of AKT, and the down-regulation of
tumor suppressor miR-375, which targets 14-3-3zeta
(Tsukamoto et al. 2010), an integral component of the
AKT pathway, has been associated with resistance to
DNA-damaging agents (Chen et al. 2010; Kovalchuk et al.
2008; Pogribny et al. 2010; Xin et al. 2009). It has been
demonstrated that enforced down-regulation of 14-3-3zeta,
w h i c hi so v e r e x p r e s s e di n4 0 %o fb r e a s tc a n c e rc a s e s ,
sensitized drug-resistant cell populations to stress-induced
apoptosis (Neal et al. 2009;N i e m a n t s v e r d r i e te ta l .2008).
Downstream of AKT, imbalances in the BCL2 super-
family, favoring cell survival over apoptosis, have also been
associated with miRNA-mediated drug resistance. Reduced
suppression of BCL2, arising from the down-regulation of
miR-15, miR-16, miR-21, miR-34, and miR-181 (Cimmino
et al. 2005; Ji et al. 2008; Zhu et al. 2010b), in cell lines
resistant to apoptosis-inducing drugs (Chen et al. 2010;
Kovalchuk et al. 2008; Zhou et al. 2010) may contribute to
the enhanced tumorigenicity and metastatic potential of
BCL2 overexpressing malignant cell populations (Del
Bufalo et al. 1997). Moreover, the BCL2 homologous
antagonist/killer (BAK1) is suppressed by overexpression
of miR-125, a biomarker of paclitaxel resistance (Zhou et
al. 2010), further supporting a reduced apoptotic program.
Studies have shown that the loss of miR-125 may increase
the sensitivity of breast cancer patients to anthracycline-
based chemotherapy (Climent et al. 2007). In contrast to
miR-125, loss of miR-127 is associated with increased cell
survival in cell lines resistant to cisplatin and doxorubicin
(Kovalchuk et al. 2008; Pogribny et al. 2010) by targeting
BCL6 (Saito et al. 2006). Several BCL2 family members
are also indirectly dysregulated by the overexpression of
miR-155 and miR-221/222, which inhibit apoptosis by
suppressing the FOXO3 transcription factor (Di Leva et al.
2010; Kong et al. 2008).
The anti-apoptotic program is further reinforced at one
of the final stages of apoptosis regulation as a result of
the effector caspase-3 being suppressed by let-7 (Tsang
and Kwok 2008), a miRNA found up-regulated in
cyclophosphamide-resistant breast cancer (Salter et al.
2008). Transfection of MDA-MB-435 breast cancer cells
with anti-apoptotic miRNAs, such as miR-145 or miR-155,
was also shown to block caspase-3 activity (Ovcharenko
et al. 2007).
Taken together, these findings suggest that numerous
miRNAs are modulated as part of a complex network
establishing an anti-apoptotic program in cells resistant to
apoptosis-inducing chemotherapeutic agents.
DNA repair
Up-regulation of DNA repair mechanisms, although
important for maintaining genetic integrity in normal
cells, has been associated with resistance to genotoxic
drugs including alkylating agents, platinum compounds,
and topoisomerase inhibitors (Reardon et al. 1999).
Activation of the nucleotide excision repair (NER)
pathway has been shown to protect cells against drug-
induced DNA damage (Reardon et al. 1999), indicating
that the down-regulation of miR-373 (Xin et al. 2009),
which suppresses the NER repair protein, RAD23B, may
facilitate DNA repair and cell survival in drug-resistant
cell lines.
Alternatively, defects in repair pathways may provide
a source of mutations contributing to the selective
evolution of progressively advanced malignant cell
populations. Tumors with defects in the mismatch repair
(MMR) pathway, which removes single-base mispairs
and mismatched loops incorporated as a result of drug
exposure, exhibit a marked resistance to the very anticancer
agents that create substrates for the MMR system (Aebi
et al. 1996). Indeed, drug-resistant breast cancer cell lines
exhibit dysregulated expression of miR-141 and miR-21,
which target two key members of the MMR system,
human DNA MutS homolog 2 (hMSH2) and 6 (hMSH6;
Bandrés et al. 2006;V a l e r ie ta l .2010).
Similarly, defects in breast cancer 1 (BRCA1), involved
in the repair of double-strand breaks and interstrand cross-
links, diminish the apoptotic response to chemotherapeutic
agents (Thangaraju et al. 2000). Although mutations in the
BRCA1 gene are well known, recent studies have shown
that variants in pri-miR-17 only occurred in a subset of
non-carriers of BRCA1/2 mutations (Shen et al. 2010) and
that miR-17, commonly up-regulated in cancer (Kovalchuk
et al. 2008; Liang et al. 2010; Salter et al. 2008), could bind
the 3′-UTR of BRCA1 mRNA (Shen et al. 2010).
Additionally, miR-28, miR-146, and miR-182 were also
shown to target BRCA1 (Yao and V entura 2011), and each
of these miRNAs has been shown to be dysregulated in
breast cancer cell lines resistant to genotoxic agents
(Kovalchuk et al. 2008; Liang et al. 2010). Additionally,
activation of BRCA1 is disrupted by deficiencies in the
DNA damage sensor, A TM (Wang et al. 2000). One
possible mechanism mediating the decrease in A TM is via
the direct targeting of the ATM gene transcript by miR-100
(Ng et al. 2010), which were found to be up-regulated in
doxorubicin-resistant cell lines (Kovalchuk et al. 2008).
This is likely to have broad repercussions for DNA repair
because BRCA1 and A TM are intimately connected to the
BRCA1-associated genome surveillance complex involved
in the recognition and repair of aberrant DNA structures
(Wang et al. 2000).
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The conversion of cancer cells from an epithelial
phenotype to a more aggressive mesenchymal phenotype
through epithelial-to-mesenchymal transition (EMT) has
been associated with multidrug resistance and poor
clinical outcome (Hiscox et al. 2004; May et al. 2011;
Nuyten et al. 2006). Indeed, one of the features of drug-
resistant cells is enhanced invasiveness, arising from the
altered expression of microtubule regulatory proteins, such
as E-cadherin and actin, and the subsequent dysregulation
of the extracellular matrix (Wang et al. 2010b)
The induction of EMT by transforming growth factor
beta (TGF-β), in coordination with the Ras and Wnt
pathways, is characterized by the dysregulation of several
key mRNAs, which may contribute, in part, to the altered
gene patterns observed during EMT (Kong et al. 2008; May
et al. 2011; Wang et al. 2010b). Up-regulation of miR-21
and miR-155 by TGF-β, whose targets include RECK,
MASPIN, TPM1, and the Ras homolog, RHOA, has been
shown to promote tumor progression, metastasis, and
multidrug resistance (Blower et al. 2007; Kong et al.
2008; Y u et al. 2010). In contrast, the enforced down-
regulation of these miRNAs has suppressed TGF-β-
induced EMT and subsequently sensitized breast cancer
cells to taxol by reducing cell viability and invasiveness
(Kong et al. 2008; Mei et al. 2010). Other miRNAs
targeting the TGF-β signaling pathway include miR-15,
miR-128, miR-141, and miR-211 (Burk et al. 2008;
Martello et al. 2007; Masri et al. 2010; Wang et al. 2010a).
TGF-β-induced EMT is often accompanied by the loss
of E-cadherin expression associated with epigenetic
remodeling at the CDH1 promoter (Tryndyak et al.
2010), as well as post-translation repression by miRNAs
(Ma et al. 2010). Indirect targeting of E-cadherin by the
miR-200 family, through the action of the transcriptional
co-repressors ZEB1 and ZEB2, has also been linked to
more aggressive breast cancers (Burk et al. 2008). This
TGF-β-driven mechanism (Korpal et al. 2008)m a y
explain the low levels of E-cadherin and high expression
of mesenchymal markers detected in breast cancer after
chemotherapy (Creighton et al. 2009), an important observa-
tion since the loss of E-cadherin increases resistance to
doxorubicin, actinomycin D, and paclitaxel (Gupta et al.
2009). Conversely, enforced expression of miR-200 inhibits
EMT by restoring E-cadherin expression through the
down-regulation of ZEB1 and ZEB2 and increases
sensitivity to microtubule-targeting agents (Cochrane et
al. 2009). Enhanced response to chemotherapeutic agents
can also be induced by depleting other E-cadherin
repressors, such as the transcription factor TWIST and
the metastasis regulator miR-9 (Li and Zhou 2011;M ae t
al. 2010). TWIST-induced activation of beta-catenin and
AKT pathways has been shown to be necessary for
the maintenance of EMT-associated cancers (Li and
Zhou 2011), suggesting a complex interplay between
mechanisms regulating cellular proliferation, apoptosis,
and cell adhesion.
miRNAs in regulating epigenetics
It is widely known that DNA methylation and histone
modifications play a prominent role in regulating the
expression of genes involved in breast cancer progression
and drug resistance; however, evidence for miRNA-
mediated epigenetic changes has only been recently been
brought to light.
DNA methylation
Aberrant DNA methylation patterns are a prominent
hallmark of cancer cells (Hanahan and Weinberg 2011).
The global loss of genomic methylation, as well as regional
hyper- and hypomethylation of genes involved in cell
signaling, proliferation, and apoptosis, is thought to favor
cell survival and tumor progression (Hanahan and
Weinberg 2011; Pogribny and Beland 2009). There are
three DNA methyltransferases (DNMTs) that have been
shown to play a prominent role in cancer-specific DNA
methylation, including maintenance DNMT1 and de novo
DNAmethyltransferasesDNMT3AandDNMT3B.Although
the mechanisms underlying elevated levels of DNMT
remain unclear, recent reports suggest a role of miR-29,
miR-148, miR-152, and miR-194 in mediating DNMT
expression (Duursma et al. 2008;F a b b r ie ta l .2007;
Meng et al. 2010; Pan et al. 2010) in drug-resistant breast
cancer cell lines (Kutanzi et al., unpublished data;
Pogribny et al. 2010). Importantly, the down-regulation
of miR-148 has been shown to correlate with tumor stage
in human breast cancer patients (Kutanzi, unpublished data),
suggesting that the loss of this miRNA may contribute to
methylation-specific patterns of tumor progression.
Hypermethylation of miR-148 by DNMTs in the early stages
of tumor development was shown to repress miR-148
gene expression (Lujambio et al. 2008), possibly indicating
that a positive feedback loop exists to reinforce the over-
expression of DNMTs in breast cancer. Furthermore,
reactivation of miR-148 upon treatment with a DNA
demethylating agent was associated with reduced tumor
growth and inhibition of metastasis (Lujambio et al. 2008).
Targeting other components of the DNA methylation
machinery has also been shown to influence methylation
patterns and contribute to tumorigenesis (Pulukuri and Rao
2006; Wada et al. 2010; Y aqinuddin et al. 2008). Indeed,
several miRNAs, such as miR-132 and miR-194, which
target the methyl-binding protein MeCP2, were also found
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doxorubicin (Kovalchuk et al. 2008; Pogribny et al. 2010).
Given that MeCP2 links DNA methylation with histone
modifications (Fuks et al. 2003), these miRNAs have the
potential to affect epigenetic-mediated drug resistance on a
large scale.
Histones
Alterations in chromatin structure have been linked to the
aberrant expression of oncogenes and tumor suppressor
genes regulating tumor progression and chemoresistance
(Baker and El-Osta 2003; Baylin 2011; Hanahan and
Weinberg 2011). Aberrant expression of chromatin-
modifying enzymes, which add functional groups to amino
acid residues on core histone tails to alter the degree of
DNA packaging, plays a key role in establishing the cancer
epigenome (Baker and El-Osta 2003; Baylin 2011).
Imbalances in histone acetyltransferase and deacetylase
expression are mediated, in part, by a number of miRNAs,
many of which are differentially expressed in parental and
drug-resistant breast cancer cell lines (Kovalchuk et al.
2008; Liang et al. 2010; Pogribny et al. 2010), which
suggests that the perturbation of chromatin remodeling
complexes may contribute to the establishment of a drug-
resistant phenotype. Furthermore, the up-regulation of
miR-101, which targets EZH2, the enzyme responsible
for trimethylating histone H3 lysine 27 to establish a
repressive chromatin state, has been linked to tamoxifen
and fulvestrant resistance (Rao et al. 2011; Sachdeva et al.
2011). Histone demethylation may also be affected by the
down-regulation of miR-342, which is predicted to target
JMJD1 demethylase, and has been linked to cisplatin
resistance (Pogribny et al. 2010). It should also be pointed
out that numerous other miRNAs aberrantly expressed in
drug-resistant tumors (Chen et al. 2010; Kovalchuk et al.
2008;P o g r i b n ye ta l .2010; Xin et al. 2009;Z h a oe ta l .
2008) have confirmed targets whose products bind to histone
remodeling complexes to influence chromatin structure.
From a rather simplistic point of view, the observation
that several different mechanisms of drug resistance exhibit
a common theme of epigenetic regulation indicates that
future studies analyzing the significance of cancer-specific
miRNA-mediated chromatin remodeling may identify novel
targets for therapeutic intervention.
miRNAs in deregulation of drug targets
The efficacy of chemotherapeutic agents is greatly
influenced by cellular events that influence drug–target
interactions. More specifically, alterations in drug target
levels, including hormone and growth factor receptors, are
often a determining factor of drug sensitivity. The identifica-
tion of miRNAs that target these receptors and their cofactors
has provided insight into the mechanisms of miRNA-
mediated resistance to hormonal and targeted therapies.
Estrogen receptor-α
Estrogen receptor (ER) expression is an important determi-
nant of endocrine responsiveness. Given that ∼70% of
breast cancers are ER-positive, many endocrine therapies,
including tamoxifen, target the steroid receptor to reduce
estrogen-driven cellular proliferation (Ariazi et al. 2006).
These drugs, however, are ineffective for treating breast
tumors that lose expression of the ER, as it often happens in
more advanced breast cancers (Ariazi et al. 2006). It has
been suggested that increased expression of miR-101,
miR-206, and miR-221/222, which translationally repress
the ER, may be responsible for the decreased sensitivity
of breast tumors to anti-estrogen drugs (Kondo et al. 2008;
Rao et al. 2011; Sachdeva et al. 2011;Z h a oe ta l .2008).
Profiling of ER-α-negative tumors has clearly identified
miR-206 and miR-221/222 as being up-regulated (Kondo et
al. 2008;Z h a oe ta l .2008), suggesting that a negative
feedback mechanism reinforces the phenotype.
miRNA-mediated targeting of ER-α cofactors, which
influence agonistic and antagonistic effects of ligand binding,
has also been linked to impaired chemotherapeutic response.
Indeed, one of the major co-activators for ER-α,a m p l i f i e di n
breast cancer (AIB1), is a target for miR-17 and miR-106,
which are found to be dysregulated in breast cancer cells
exhibitingdrugresistance(Kovalchuketal.2008; Liang et al.
2010). Similarly, the transcriptional co-repressor, receptor
interacting protein 140 (RIP140), was found to be targeted
by miR-346, which is down-regulated in endocrine-resistant
cell lines (Xin et al. 2009), indicating a role for miRNAs in
regulating estrogen-responsive genes.
Epidermal growth factor receptor
Overexpression of the human epidermal growth factor
(HER) family members occurs in ∼20–25% of invasive
breast cancer cases and correlates with poor patient
prognosis (Murphy and Modi 2009). Over half of the
breast cancer patients who undergo HER2-targeted therapy
with trastuzumab fail to respond. It has been speculated that
drug efficacy is reduced by the continuous overexpression
of the drug target, a phenomenon that may be mediated by
the down-regulation of miR-125 and miR-331 (Kovalchuk
et al. 2008) whose normal function is to suppress HER2.
Moreover, high expression of HER2 in cancer cells has
been shown to induce ligand-independent constitutive
activation of the receptor and its downstream MAPK and
PI3K signaling pathways, thereby facilitating cross talk
with the ER to induce multidrug resistance (Britton et al.
180 Clin Epigenet (2011) 2:171–1852006). miRNA-based suppression of EGFR-induced PI3K
activation, including the repression of other EGFR
members, such as HER3 by miR-205 (Iorio et al. 2009),
may be an important avenue to explore for re-sensitizing
breast cancer cells that have acquired cross-resistance to
chemotherapeutic agents.
Limitations and future considerations
Clearly, aberrant expression of miRNAs is an important
feature of cancer cells with an acquired drug-resistant
phenotype and may be a critical factor contributing to its
development. Indeed, miRNAs are implicated in several
cellular responses to drug exposure, including, but not limited
to, drug influx/efflux, cell cycle arrest, DNA repair, and
apoptosis, all of which mediate cancer cell survival and tumor
progression. The dysregulation of similar pathways in cancer
cells exhibiting resistance to a wide range of drugs may
explain the existence, and provide a mechanism, of cross-
resistance to different types of chemotherapeutic agents.
Despite the growing evidence of cancer-specific miRNA
patterns, the role of miRNAs in cancer is complex and
difficult to unravel. The downstream effects of even a single
miRNA are complicated by the number of targets it may
have, with predictions ranging from one to hundreds of
transcripts (Xin et al. 2009). Moreover, several miRNAs,
which may be differentially regulated, can target the
transcript of a single gene, making it difficult to predict
the net result. It is believed, however, that mRNAs targeted
by multiple down-regulated miRNAs are more likely to be
overexpressed than mRNAs targeted by a single miRNA
(Xin et al. 2009) and that mRNAs possessing multiple
target sites for similarly expressed miRNAs have a greater
probability of being affected than those with only one site
(Xin et al. 2009). Furthermore, since a number of miRNAs
can target DNA and histone-modifying enzymes, they are
likely to affect gene expression on a much broader scope.
For this reason, studies need to address the wide range of
effects of even a single dysregulated miRNA in order to
completely understand the complex network of feedback
mechanisms and cross talk between pathways. To
complicate matters further, recent papers demonstrate
that miRNA function is tissue-specific and context-
dependent, switching from repressors to activators in
different circumstances (Liu and Kohane 2009; V asudevan et
al. 2007). From a clinical perspective, given that miRNAs
can induce a diversity of effects, caution must be exercised
when extrapolating findings from in vitro to in vivo.
Despite the difficulties to overcome, the value of
miRNAs in clinical applications is projected to be monu-
mental. Indeed, miRNA profiling has been convincingly
demonstrated to classify tumor and non-tumor samples
more effectively than gene expression profiling and,
more importantly, identifying breast cancer subtypes
(Blenkiron et al. 2007;I o r i oe ta l .2005;L ue ta l .2005).
The diagnostic role of miRNAs is crucial since different
breast cancer subtypes exhibit different responsiveness to
chemotherapeutic agents (Carey et al. 2007; Rouzier et al.
2005). In the future, predicting responses to cytotoxic
therapy will ideally involve a combination of gene
expression data, miRNA profiling, and receptor status
determination, with the goal of developing a personalized
treatment strategy to improve patient outcome. Current
studies are also investigating the value of miRNAs as early
plasma biomarkers, with the expectation that they will
exhibit a greater degree of specificity and sensitivity over
the current biomarkers (Heneghan et al. 2010; Lodes et al.
2009;R o t he ta l .2010;Z h a oe ta l .2010a). The detection
of cancer-specific miRNAs in plasma provides a relatively
noninvasive method for monitoring predictive markers
(Heneghan et al. 2010; Lodes et al. 2009). Moreover,
profiling of miRNAs that regulate genes known to be
predictive of drug resistance can potentially be used in
guiding drug treatment decisions.
Evidence of miRNA-mediated reversal of multidrug
resistance in human cancer (Zhang et al. 2010; Zhao et al.
2010c) warrants further studies of miRNA-based
approaches for treating drug-resistant tumors. One of the
most promising therapeutic targets is miR-21, commonly
found to be up-regulated in breast cancer, which is
associated with enhanced metastatic potential and drug
resistance. In a systematic search for miRNAs mediating
drug efficacy, miR-21 was identified as having the capacity
to alter the potency of a wide range of chemotherapeutic
agents by up to fourfold (Blower et al. 2007), which
suggests that targeting miR-21 may enhance sensitivity to
multiple chemotherapeutic drugs. Indeed, enforced down-
regulation of miR-21 has been shown to increase levels of
PTEN and caspase-3, which are associated with an
increased number of apoptotic cells and reduced invasive-
ness leading to drug sensitivity (Bourguignon et al. 2009;
Mei et al. 2010; Ren et al. 2010). Preliminary evidence has
also demonstrated the viability of delivering both miRNA
and drug treatments at the same time to improve the
response to chemotherapeutic agents. A study by Mei et al.
(2010) showed that a G5-PAMAM dendrimer could be
utilizedtodeliveramiR-21inhibitorandtaxolsimultaneously
to effectively reduce tumor growth and invasiveness. In
the future, miRNA-based treatments, in combination with
traditional chemotherapy, may be a new strategy for the
clinical management of drug-resistant breast cancers.
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